Journal article
PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide
Abstract
RATIONALE: PSA responses have been associated with a survival benefit in patients treated with enzalutamide in retrospective analyses.
PATIENT CONCERNS: However the prognostic value of PSA declines in highly pretreated patients receiving enzalutamide remains to be defined.
Authors
Bosso D; Pagliuca M; Sonpavde G; Pond G; Lucarelli G; Rossetti S; Facchini G; Scagliarini S; Cartenì G; Daniele B
Journal
Medicine, Vol. 96, No. 24,
Publisher
Wolters Kluwer
Publication Date
June 2017
DOI
10.1097/md.0000000000006817
ISSN
0025-7974